Guidelines for the management of adverse events following CD19 CAR-T cell therapy in adult patients with lymphomas and acute lymphoblastic leukemia: consensus of expert panel from certified centers in Czechia and Slovakia for 2025

Česko-slovenská konsenzuální doporučení pro řešení toxicity CD19 CAR-T lymfocytů

Abstract

Autologous chimeric antigen receptor T-cells (CAR-T cells) have become a standard of care for hematological malignancies, particularly non-Hodgkin B-cell lymphomas and acute B-lymphoblastic leukemia. An expert panel from all certified centers in Czechia and Slovakia presents these guidelines for the grading, prophylaxis and treatment of common adverse events. These include cytokine release syndrome, neurotoxicity syndrome, hematological toxicity, infections, and other less frequent but specific toxicities. These guidelines are adapted to the local state-of-the-art and are supplemented with concise summary tables designed for use in daily clinical practice.